NCT00146094

Bone Mineral Density (BMD) in HIV Infection

Osteopenia and Osteoporosis in HIV Infection. Prospective BMD Measurement in Antiretroviral (ARV) Treated and Untreated HIV-1 Infected Patients

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Osteopenia and osteoporosis are increasingly reported in HIV-infected patients, and appear to be more frequent than in general population. However, pathogenesis remains unclear, and published studies still give non concordant results. We therefore started a prospective study, to assess the potential role of ARV in the occurrence of osteopenia and osteoporosis. BMD evolution over a 2-years period of follow-up, will be compared between patients starting ARV therapy, and subjects without HAART (no indication of treatment). A correlation between BMD and several factors will be looked at (see below). This study with individual direct benefice, is conducted in 3 outpatients clinics (Strasbourg, Colmar, Mulhouse) in collaboration with the rheumatologic teams. 60 patients are planned to be included over a 3-years inclusion period

Conditions

• Osteopenia
• Osteoporosis

Interventions

Type	Name	Description
PROCEDURE	BMD Measurement
DRUG	antiretrovirals	Treated with antiretrovirals

Timeline

• Start date: 2003-03-01
• Primary completion: 2003-03-01
• Completion: 2006-12-14
• First posted: 2005-09-05
• Last updated: 2025-09-26

Locations

3 sites across 1 country: France